Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 868 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dose Finding Study Clear all
Recruiting Phase 2 Interventional

A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease

NCT06613698
View directory record Official record
Conditions
Liver Diseases, Alcoholic
Interventions
GSK4532990, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
34
States / cities
Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 2 Interventional Results available

Vitamin D Dose Finding Study

NCT01092338
View directory record Official record
Conditions
HIV Infections, AIDS
Interventions
Cholecalciferol (Vit D3)
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
5 Years to 24 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 18, 2013 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose-Finding Study of CS19 Expressing ETEC Challenge Strains

NCT00564863
View directory record Official record
Conditions
Travelers' Diarrhea
Interventions
CS19 expressing ETEC strain
Biological
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 1 Interventional

ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors

NCT00132158
View directory record Official record
Conditions
Glioblastoma, Rhabdomyosarcomas, Neuroblastoma, Osteosarcoma
Interventions
Irinotecan (Camptosar), Gefitinib (Iressa)
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 17, 2012 · Synced Oct 22, 2026, 5:32 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Dose-Finding of Retinoid 9cUAB30 in Healthy Volunteers

NCT01336387
View directory record Official record
Conditions
Healthy, no Evidence of Disease
Interventions
retinoid 9cUAB30, placebo, pharmacological study, laboratory biomarker analysis, cancer prevention
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 9, 2014 · Synced Oct 22, 2026, 5:32 AM EDT
Recruiting Phase 1 Interventional

Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC

NCT06912087
View directory record Official record
Conditions
Head and Neck Neoplasms, Carcinoma, Squamous Cell, Neoplasm Recurrence, Local, Neoplasm Metastasis, Recurrent Squamous Cell Carcinoma, Metastatic Squamous Cell Carcinoma
Interventions
Zanzalintinib, Cetuximab, Pembrolizumab
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 22, 2026, 5:32 AM EDT
Terminated Phase 2 Interventional Results available

A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults

NCT04493216
View directory record Official record
Conditions
HIV Infections
Interventions
GSK3640254, ABC/3TC, FTC/TAF, Dolutegravir, Placebo
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
9
States / cities
Los Angeles, California • Ft. Pierce, Florida • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 22, 2026, 5:32 AM EDT
Recruiting Phase 1 Interventional

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

NCT07012044
View directory record Official record
Conditions
Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine, Decitabine and Cedazuridine, Filgrastim, Imaging Procedure, Lumbar Puncture
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
14
States / cities
Birmingham, Alabama • Aurora, Colorado • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 22, 2026, 5:32 AM EDT
Recruiting Phase 2 Interventional

Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids

NCT06932263
View directory record Official record
Conditions
Asthma
Interventions
Tozorakimab, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
64
States / cities
Bakersfield, California • Huntington Beach, California • La Mesa, California + 60 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 22, 2026, 5:32 AM EDT
Recruiting Phase 1 Interventional

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

NCT04729114
View directory record Official record
Conditions
Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer
Interventions
PRL-02 injection, prednisone, dexamethasone, enzalutamide
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
24
States / cities
Tucson, Arizona • Anaheim, California • Santa Rosa, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 2 Interventional Results available

Study to Find Out the Optimal Dose of Caffeine in the Combination Tablet of Naproxen Sodium and Caffeine in Patients Experiencing Moderate to Severe Pain After Having Wisdom Teeth Removed

NCT04132336
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Naproxen sodium/Caffeine (BAY2880376), Naproxen sodium (Aleve), Caffeine, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
16 Years and older
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Oct 22, 2026, 5:32 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients

NCT00699842
View directory record Official record
Conditions
Myelodysplastic Syndrome, MDS, Low to Intermediate-1 MDS, Non-deletion 5q
Interventions
Lenalidomide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Chester, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals

NCT04368728
View directory record Official record
Conditions
SARS-CoV-2 Infection, COVID-19
Interventions
BNT162b1, BNT162b2, Placebo, BNT162b2SA
Biological · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
12 Years and older
Enrollment
46,969 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
154
States / cities
Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 106 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 22, 2026, 5:32 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)

NCT02584634
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Avelumab, PF-06463922, Crizotinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
7
States / cities
Atlanta, Georgia • Boston, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults

NCT00973349
View directory record Official record
Conditions
Influenza
Interventions
MF59-eH1N1_f
Biological
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
2,719 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
20
States / cities
Miami, Florida • Lenexa, Kansas • Omaha, Nebraska + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Part 1: Dose-Finding of HSK3486 Injection In Nondependent, Recreational Central Nervous System Depressant Users

NCT07404306
View directory record Official record
Conditions
General Anesthesia
Interventions
HSK3486, propofol, Placebo
Drug
Lead sponsor
Haisco-USA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 1 Interventional

Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients

NCT05002140
View directory record Official record
Conditions
Metastasis, Locally Advanced Solid Tumor, Recurrent Cancer
Interventions
XRD-0394, Palliative radiotherapy
Drug · Radiation
Lead sponsor
XRad Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Stanford, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Oct 22, 2026, 5:32 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission

NCT01656252
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Phase I- Cytarabine & Eltrombopag, Phase II- Sequence A, Phase II- Sequence B
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
5
States / cities
Worcester, Massachusetts • Rochester, Minnesota • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 1 Interventional

Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer

NCT00976131
View directory record Official record
Conditions
Breast Cancer
Interventions
CoQ10, CoQ10 Placebo, Doxorubicin, Cyclophosphamide
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
21 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Oct 22, 2026, 5:32 AM EDT
Terminated Phase 1 Interventional

A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors

NCT03355066
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
SM08502
Drug
Lead sponsor
Biosplice Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
19
States / cities
Scottsdale, Arizona • Tucson, Arizona • Duarte, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Relative Bioavailability of a New Formulation Compared With the Approved Formulation of rhPTH [1-84] and to Find Out Dose Linearity of the New Formulation in Healthy Adults

NCT05137730
View directory record Official record
Conditions
Healthy Volunteers
Interventions
rhPTH(1-84)
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors

NCT00951405
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions
activated recombinant human factor VII, long acting
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years to 65 Years · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
7
States / cities
Little Rock, Arkansas • Los Angeles, California • Orange, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 22, 2026, 5:32 AM EDT
Terminated Phase 2 Interventional Results available

Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection

NCT01199731
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK2248761 100 mg once daily, GSK2248761 200 mg once daily, Etravirine
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 1 Interventional

Dose-Finding Pilot Study of ACTH in Patients With Idiopathic Membranous Nephropathy

NCT00805753
View directory record Official record
Conditions
Idiopathic Membranous Nephropathy
Interventions
ACTH
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 13, 2014 · Synced Oct 22, 2026, 5:32 AM EDT